Overview


According to FutureWise analysis the market for implantable drug eluting devices in 2023 is US$ 13.6 billion, and is expected to reach US$ 22.03 billion by 2031 at a CAGR of 6.22%.

Drug-eluting medical devices are active implants that, in addition to their primary function of support, also have the ability to generate therapeutic benefits. Controlled release of active pharmaceutical ingredients (API) into the surrounding tissue is used to achieve this effect. Each of these drug-eluting devices also offers a solution to the problem of drug release. The majority of drug-eluting vascular stents contain water-insoluble antiproliferative drugs, which take a long time to diffuse from the device to the surrounding tissue. When it comes to cardiology, ophthalmology, birth control, opioid addiction, pain management, diabetes management, contraception, and cancer therapy, implanted drug eluting devices are indispensable. The customised medication delivery systems help to increase treatment efficacy (oncology and cardiology) and reduce side effects by limiting damage to healthy tissue. Active drug eluting devices and passive drug eluting devices are the two basic types of implanted drug eluting devices.

Electromechanical and osmotic pressure gradient technologies are primarily used in active drug eluting devices. Over the projected period, the market for implantable drug eluting devices is expected to rise at a healthy pace. This expansion is linked to the increasing use of patient-controlled devices and the increased incidence of peripheral and coronary artery disorders. Furthermore, the global market for implantable drug eluting devices is expected to develop as the incidence of cardiovascular and chronic diseases continues to rise. According to the World Health Organization, cardiovascular disease is one of the main causes of death worldwide. A number of research and clinical studies are under underway to improve the performance of existing drug-eluting stents and devices. Thus, research in this area focuses on the evaluation and development of innovative and enhanced drug eluting devices that provide significant clinical benefits while also addressing long-term safety issues.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Implantable Drug Eluting Devices Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Implantable Drug Eluting Devices Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Pfizer Inc.
  • Medtronic Inc.
  • MerckCo., In
  • Bayer AG
  • JOHNSON and JOHNSON
  • SurModics Inc.
  • AstraZeneca Plc.
  • Boston Scientific Corporation
  • Titan Pharmaceuticals, Inc.
  • BIOTRONIK, INC.
  • Abbott Laboratories
  • Allergan, Inc.
  • Bausch and Lomb, Inc.
  • Alimera Sciences
  • REVA Medical, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Implantable Drug Infusion Pumps
  • Intraocular Drug Eluting Devices
  • Contraceptive Drug Eluting Devices
  • Buprenorphine Implant
  • Drug Eluting Stents
  • Others

By Technology

  • Active Drug Eluting Device
  • Passive Drug Eluting Device
    • Biodegradable Implants
    • Non-Biodegradable Implants

By Application

  • Diabetic Macular Edema
  • Birth Control/Contraception
  • Opioid Addiction
  • Cardiovascular
  • Ophthalmology
  • Oncology
  • Pain Management

By Implementation Type

  • Intravaginal
  • Intravascular
  • Intraocular
  • Intrathecal
  • Subcutaneous
  • Intrauterine

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Optical Care Centers
  • Cardiac Surgery Centers
  • Office Based Settings
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Implantable Drug Eluting Devices Market By Product, By Technology, By Application, By Implementation Type, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Implantable Drug Eluting Devices Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Implantable Drug Eluting Devices Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Implantable Drug Eluting Devices Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Implantable Drug Eluting Devices Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Implantable Drug Infusion Pumps
        2. Intraocular Drug Eluting Devices
        3. Contraceptive Drug Eluting Devices
        4. Buprenorphine Implant
        5. Drug Eluting Stents
        6. Others

  • 8.   Implantable Drug Eluting Devices Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Active Drug Eluting Device
        2. Passive Drug Eluting Device
         2.1. Biodegradable Implants
         2.2. Non-Biodegradable Implants

  • 9.   Implantable Drug Eluting Devices Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Diabetic Macular Edema
        2. Birth Control/Contraception
        3. Opioid Addiction
        4. Cardiovascular
        5. Ophthalmology
        6. Oncology
        7. Pain Management

  • 10.   Implantable Drug Eluting Devices Market, By Implementation Types Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Intravaginal
        2. Intravascular
        3. Intraocular
        4. Intrathecal
        5. Subcutaneous
        6. Intrauterine

  • 11.   Implantable Drug Eluting Devices Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Ambulatory Surgical Centers
        3. Optical Care Centers
        4. Cardiac Surgery Centers
        5. Office Based Settings
        6. Others

  • 12.   North America Implantable Drug Eluting Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Implantable Drug Eluting Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Implantable Drug Eluting Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Implantable Drug Eluting Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Medtronic Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Merck & Co., In
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bayer AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Johnson & Johnson
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. SurModics Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. AstraZeneca Plc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Boston Scientific Corporation
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Titan Pharmaceuticals, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. BIOTRONIK, INC.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Abbott Laboratories
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Allergan, Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Bausch and Lomb, Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Alimera Sciences
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. REVA Medical, Inc.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients